Evaluation of a Tailored Virtual Intervention to Empower Persons Living With HIV for Therapy Self-management (HIVMediconline)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01510340|
Recruitment Status : Suspended (Changes & upgrades in informatic infrastructure of the web-based intervention.)
First Posted : January 16, 2012
Last Update Posted : January 25, 2018
|Condition or disease||Intervention/treatment||Phase|
|HIV||Behavioral: VIH-TAVIE||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||234 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Study Start Date :||January 2012|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||June 2019|
No Intervention: Web sites
Patients assigned to this arm are given a list of Web sites where they can collect information related to their condition at their leisure.
Patients assigned to this arm must follow the four interactive computer sessions
The tailored virtual intervention is composed of four interactive computer sessions hosted by a virtual nurse who engages the PLHIV in a medication-intake self-management skills-learning process.
- Adherence [ Time Frame: 6 months ]Adherence will be evaluated through a self-administered questionnaire that was developed for and validated on the targeted population (Godin, Gagné, & Naccache, 2003). The questionnaire comprises seven items that serve to determine how many times a person forgets to take his or her medication. The questionnaire's validity was demonstrated (sensitivity: 71 %; specificity: 72%; correct classification: 72%; odds ratio: 6.15) using immunologic (CD4 count) and virologic (viral load) parameters as validation criteria. Adherence is defined as the intake of at least 95% of prescribed tablets.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01510340
|Montréal, Quebec, Canada, H2X 0A9|
|Principal Investigator:||José Côté, Ph.D.||CRCHUM, Université de Montréal|
|Study Chair:||Gaston Godin, Ph.D.||Laval University|
|Study Chair:||Yann-Gael Guéhéneuc, Ph.D.||Polytechnique|
|Study Chair:||Cécile Tremblay, MD,Ph.D.||CRCHUM|
|Study Chair:||Joanne Otis, Ph.D.||Universite du Quebec a Montreal|